Most Shorted Stocks
NTLA is part of our most shorted stocks screen list, indicating it has a high short interest.
INTELLIA THERAPEUTICS INC (NTLA) Stock Price & Overview
NASDAQ:NTLA • US45826J1051
Current stock price
14.16 USD
-0.78 (-5.22%)
At close:
14.16 USD
0 (0%)
After Hours:
The current stock price of NTLA is 14.16 USD. Today NTLA is down by -5.22%. In the past month the price increased by 7.19%. In the past year, price increased by 95.85%.
NTLA Key Statistics
52-Week Range6.83 - 28.25
Current NTLA stock price positioned within its 52-week range.
1-Month Range11.62 - 15.275
Current NTLA stock price positioned within its 1-month range.
- Market Cap
- 1.673B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.83
- Dividend Yield
- N/A
NTLA Stock Performance
Today
-5.22%
1 Week
+2.39%
1 Month
+7.19%
3 Months
+13.28%
Longer-term
6 Months -42.79%
1 Year +95.85%
2 Years -33.83%
3 Years -62.49%
5 Years -81.56%
10 Years N/A
NTLA Stock Chart
NTLA Stock Screens
NTLA currently appears in the following ChartMill screener lists.
NTLA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NTLA. When comparing the yearly performance of all stocks, NTLA is one of the better performing stocks in the market, outperforming 90% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NTLA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NTLA. NTLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NTLA Earnings
On February 26, 2026 NTLA reported an EPS of -0.83 and a revenue of 23.02M. The company beat EPS expectations (14.78% surprise) and beat revenue expectations (76.48% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.83
Revenue Reported23.017M
EPS Surprise 14.78%
Revenue Surprise 76.48%
NTLA Forecast & Estimates
30 analysts have analysed NTLA and the average price target is 25.16 USD. This implies a price increase of 77.68% is expected in the next year compared to the current price of 14.16.
For the next year, analysts expect an EPS growth of 3.93% and a revenue growth 8.99% for NTLA
Analysts
Analysts74
Price Target25.16 (77.68%)
EPS Next Y3.93%
Revenue Next Year8.99%
NTLA Groups
Sector & Classification
NTLA Financial Highlights
Over the last trailing twelve months NTLA reported a non-GAAP Earnings per Share(EPS) of -3.83. The EPS increased by 27.05% compared to the year before.
Income Statements
Revenue(TTM)67.67M
Net Income(TTM)-412.69M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.01% | ||
| ROE | -61.47% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%34.65%
Sales Q2Q%78.79%
EPS 1Y (TTM)27.05%
Revenue 1Y (TTM)16.92%
NTLA Ownership
Ownership
Inst Owners85.68%
Shares118.13M
Float112.40M
Ins Owners1.61%
Short Float %34.65%
Short Ratio10.57
NTLA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 368.645B | ||
| AMGN | AMGEN INC | 15.3 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.37 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.91 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 10.92 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.86 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.32 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NTLA
Company Profile
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Company Info
IPO: 2016-05-06
INTELLIA THERAPEUTICS INC
40 Erie St Ste 130
Cambridge MASSACHUSETTS 02139 US
CEO: John M. Leonard
Employees: 377
Phone: 18572856200
INTELLIA THERAPEUTICS INC / NTLA FAQ
What does INTELLIA THERAPEUTICS INC do?
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
What is the stock price of INTELLIA THERAPEUTICS INC today?
The current stock price of NTLA is 14.16 USD. The price decreased by -5.22% in the last trading session.
Does NTLA stock pay dividends?
NTLA does not pay a dividend.
How is the ChartMill rating for INTELLIA THERAPEUTICS INC?
NTLA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in INTELLIA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NTLA.
Can you provide the ownership details for NTLA stock?
You can find the ownership structure of INTELLIA THERAPEUTICS INC (NTLA) on the Ownership tab.
What is the Short Interest ratio of INTELLIA THERAPEUTICS INC (NTLA) stock?
The outstanding short interest for INTELLIA THERAPEUTICS INC (NTLA) is 34.65% of its float.